NLRP3 and leukemia: Chemotherapy induces upregulation of NLRP3, and interestingly, the triterpenoid analog CDDO-2P-Im (1-(2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl)-4(-pyridin-2-yl)-1H-imidazole) inhibits NLRP3 inflammasome activation, reduces ALL cell growth in vitro, and promotes apoptosis in steroid-sensitive and steroid-resistant leukemia cells [67].